Actualización del tratamiento del cáncer de próstata avanzado y de sus complicaciones Journal Article

Fulltext large  

Authors: Gil-Bazo, I.; Martínez-Salamanca, J. I.; Bianco, F. J. Jr
Article Title: Actualización del tratamiento del cáncer de próstata avanzado y de sus complicaciones
Abstract: Prostate adenocarcinoma is the leading cause of cancer in Spain, among men older than 65. 1,200 new cases out of every 100,000 males are diagnosed with prostate cancer on an annual basis. In the United States, this illness represents the second leading cause of death due to cancer in males. In those patients whose prostate tumors progress after surgery or radiotherapy, or have metastatic disease when diagnosed, a systemic approach in order to improve their quality of life and overall survival is mandatory. First line hormone therapies usually reach a proper control of the tumor maintaining an acceptable quality of life. However, most of these tumors becomes androgen-independent over time and behave as a more aggressive cancer type. In these patients, combination therapy protocols have recently demonstrated a benefit not only in terms of symptoms control and response rates but also in improving survival. In addition, several new molecules are currently under study. The accurate knowledge of the symptoms due to disease spreading as well as treatment's side effects is necessary to provide an appropriate palliative management that contributes to an improvement of the quality of life in advanced prostate cancer patients.
Keywords: cancer survival; cancer surgery; unclassified drug; prednisone; neutropenia; review; doxorubicin; advanced cancer; cancer growth; diarrhea; cancer radiotherapy; treatment; anorexia; treatment indication; adenocarcinoma; ipilimumab; metastasis; quality of life; infection; mucosa inflammation; nausea; vomiting; myalgia; cetuximab; docetaxel; monoclonal antibody; asthenia; prostate cancer; prostatic neoplasms; cause of death; prostatectomy; disease progression; mitoxantrone; glucocorticoid; complications; antiemetic agent; prostate adenocarcinoma; bicalutamide; flutamide; gonadorelin derivative; cancer control; anthracycline derivative; trastuzumab; alopecia; bone marrow toxicity; analgesic agent; omeprazole; serotonin 3 antagonist; spain; pantoprazole; estramustine
Journal Title: Medicina Clínica
Volume: 125
Issue: 17
ISSN: 0025-7753
Publisher: Elsevier Inc.  
Date Published: 2005-11-12
Start Page: 671
End Page: 677+xii
Language: Spanish
PUBMED: 16324498
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-29044434574&partnerID=40&md5=12107abee52bb969d88bcae7af8d5249
Notes: --- [Update of the treatment of advanced prostate cancer and management of its complications] - "Cited By (since 1996): 1" - "Export Date: 24 October 2012" - "Art. No.: 106.121" - "CODEN: MCLBA" - "Source: Scopus"